Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 14/20 | 0.51 |
| ▸ | MERTK | Q12866 | 1/20 | 0.51 |
| ▸ | MET | P08581 | 4/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.48 |
| ▸ | SRC | P12931 | 2/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29487144 | 1.00 | AXL (0.51) | AXLMERTKMETKDRPDGFRA | |
| SCHEMBL21083204 | 0.89 | KDR (0.57) | AXLMERTKMETKDRPDGFRA | |
| SCHEMBL1132195 | 0.89 | AXL (0.62) | AXLMERTKMETKDRPDGFRA | |
| SCHEMBL1132352 | 0.88 | AXL (0.55) | AXLMERTKMETKDRPDGFRA | |
| SCHEMBL30066135 | 0.88 | AXL (0.55) | AXLMERTKMETKDRPDGFRA | |
| SCHEMBL1132601 | 0.86 | AXL (0.60) | AXLMERTKMETKDRPDGFRA | |
| SCHEMBL29487165 | 0.86 | AXL (0.60) | AXLMERTKMETKDRPDGFRA | |
| SCHEMBL1896276 | 0.85 | KDR (0.55) | AXLMERTKMETKDRPDGFRA | |
| SCHEMBL166914 | 0.83 | AXL (0.67) | AXLMETKDRPDGFRASRC | |
| Hydrochloric Acid SCHEMBL21776567 | 0.82 | AXL (0.66) | AXLMETKDRPDGFRASRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220235064-A1 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | WELLMARKER BIO CO., LTD. (KR) | 2022-07-28 | — | — | US | disclosed |
| EP-4011885-A1 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Wellmarker Bio Co., Ltd. (KR) | 2022-06-15 | — | — | EP | disclosed |
| EP-4011885-A1 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Wellmarker Bio Co., Ltd. (KR) | 2022-06-15 | — | — | EP | disclosed |
| WO-2021025407-A1 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 웰마커바이오 주식회사 | 2021-02-11 | — | — | WO | disclosed |
| WO-2021025407-A1 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 웰마커바이오 주식회사 | 2021-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235064-A1 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ROS1, ROR1, RET | AXL 377/4885MERTK 518/4885MET 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.